Julien BRANCHU

EverZom stands among the pioneers in exosome-based therapies, a significant revolution in the current therapeutic landscape of gene and cell therapies. Exosomes are biological nanoparticles secreted by cells that currently raise growing interest within the pharmaceutical industry due to their potent role in intercellular communication. They hold promising properties for treating a wide range of diseases with high unmet medical need. Winner of the European EIC Accelerator Program, EVerZom aims to become the leading biotech in this field. The company has successfully developed an innovation platform protected by several patents, covering the entire technological value chain: cell sourcing, exosome generation, exosome loading, and formulation. By leveraging its platform, EVerZom aims to develop a pipeline of proprietary products in regenerative medicine, while establishing co-development partnerships in other therapeutic areas.